TriangleAndrogen Deprivation Therapy (ADT) (NCT05790213)
Androgen Deprivation Therapy (ADT) trial for Prostate Cancer (NCT05790213). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with untreated, intermediate-risk prostate cancer confined to the prostate, who have chosen focal therapy and can undergo anesthesia. Suspected seminal-vesicle involvement needs a negative biopsy.
The idea: three months of doctor-selected androgen deprivation precedes focal ablation. This procedure destroys the affected part of the prostate. Researchers use MRI to assess residual cancer in treated and untreated tissue and record complications. Eligibility includes specific grade, PSA, and biopsy limits.
This phase 2 study plans 57 patients. Abhinav Sidana leads at UChicago, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.